News|Articles|August 4, 2026

FDA updates in urology: July 2026

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

Welcome to Urology Times’® monthly FDA update! This month’s regulatory news featured several practice-changing developments across bladder and prostate cancer, with key approvals in muscle-invasive bladder cancer (MIBC) and metastatic castration-sensitive prostate cancer (mCSPC). The agency also advanced the treatment landscape through a priority review decision in prostate cancer and a tentative approval for a generic oncology drug, signaling continued momentum in genitourinary cancers.